Cargando…
Evaluation of Drugs with Therapeutic Potential for Susceptibility of Neisseria Gonorrhoeae Isolates from 8 Provinces in China from 2018
PURPOSE: The study aimed to evaluate meropenem, fosfomycin, berberine hydrochloride, and doxycycline minimum inhibitory concentrations (MICs) of Neisseria gonorrhoeae collected from eight provinces in China in 2018. METHODS: The MICs of 540 Neisseria gonorrhoeae isolates (451 isolates selected rando...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7751583/ https://www.ncbi.nlm.nih.gov/pubmed/33364794 http://dx.doi.org/10.2147/IDR.S278020 |
_version_ | 1783625694367973376 |
---|---|
author | Zheng, Xiao-Li Xu, Wen-Qi Liu, Jing-Wei Zhu, Xiao-Yu Chen, Shao-Chun Han, Yan Dai, Xiu-Qin Goodman, Isabelle Griffin Budjan, Christoph Chen, Xiang-Sheng Yin, Yue-Ping |
author_facet | Zheng, Xiao-Li Xu, Wen-Qi Liu, Jing-Wei Zhu, Xiao-Yu Chen, Shao-Chun Han, Yan Dai, Xiu-Qin Goodman, Isabelle Griffin Budjan, Christoph Chen, Xiang-Sheng Yin, Yue-Ping |
author_sort | Zheng, Xiao-Li |
collection | PubMed |
description | PURPOSE: The study aimed to evaluate meropenem, fosfomycin, berberine hydrochloride, and doxycycline minimum inhibitory concentrations (MICs) of Neisseria gonorrhoeae collected from eight provinces in China in 2018. METHODS: The MICs of 540 Neisseria gonorrhoeae isolates (451 isolates selected randomly and 89 isolates selected with preference) were determined to meropenem, fosfomycin, berberine hydrochloride, and doxycycline using the agar dilution method, and the MICs of ceftriaxone and azithromycin were detected for comparison. RESULTS: Among 451 randomly selected isolates, the MIC(90) was 0.06 mg/L for meropenem, 64 mg/L for fosfomycin, 64 mg/L for berberine hydrochloride, and 16 mg/L for doxycycline. All isolates showed the MIC ≤ 0.125 mg/L to meropenem, 13 isolates (2.9%) showed MIC > 64 mg/L to fosfomycin, 8 isolates (1.8%) demonstrated MIC > 64 mg/L to berberine hydrochloride, and 271 isolates (60.1%) demonstrated MIC > 1 mg/L to doxycycline. Comparing all 540 tested isolates, a correlation of r = 0.50 (P < 0.001) between meropenem and ceftriaxone MIC was observed. In 24 ceftriaxone-decreased susceptibility isolates, all isolates showed an MIC ≤ 0.125 mg/L for meropenem, 1 isolate (4.2%) showed an MIC > 64 mg/L for fosfomycin, 1 isolate (4.2%) showed an MIC > 64 mg/L for berberine hydrochloride, and 13 isolates (54.2%) showed an MIC > 1 mg/L for doxycycline. In 87 azithromycin resistant isolates, all isolates showed an MIC ≤ 0.125 mg/L for meropenem, 2 isolates (2.3%) showed an MIC > 64 mg/L for fosfomycin, 4 isolates (4.6%) showed an MIC > 64 mg/L for berberine hydrochloride, and 64 isolates (73.6%) showed an MIC > 1 mg/L for doxycycline. CONCLUSION: The in vitro results suggest that meropenem might be a promising treatment option for resistant gonococcal infections, while the effects of fosfomycin and berberine hydrochloride should be further evaluated as potential therapeutic agents. The effectiveness of these drugs in animal experiments and clinical use may need further study. |
format | Online Article Text |
id | pubmed-7751583 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-77515832020-12-22 Evaluation of Drugs with Therapeutic Potential for Susceptibility of Neisseria Gonorrhoeae Isolates from 8 Provinces in China from 2018 Zheng, Xiao-Li Xu, Wen-Qi Liu, Jing-Wei Zhu, Xiao-Yu Chen, Shao-Chun Han, Yan Dai, Xiu-Qin Goodman, Isabelle Griffin Budjan, Christoph Chen, Xiang-Sheng Yin, Yue-Ping Infect Drug Resist Original Research PURPOSE: The study aimed to evaluate meropenem, fosfomycin, berberine hydrochloride, and doxycycline minimum inhibitory concentrations (MICs) of Neisseria gonorrhoeae collected from eight provinces in China in 2018. METHODS: The MICs of 540 Neisseria gonorrhoeae isolates (451 isolates selected randomly and 89 isolates selected with preference) were determined to meropenem, fosfomycin, berberine hydrochloride, and doxycycline using the agar dilution method, and the MICs of ceftriaxone and azithromycin were detected for comparison. RESULTS: Among 451 randomly selected isolates, the MIC(90) was 0.06 mg/L for meropenem, 64 mg/L for fosfomycin, 64 mg/L for berberine hydrochloride, and 16 mg/L for doxycycline. All isolates showed the MIC ≤ 0.125 mg/L to meropenem, 13 isolates (2.9%) showed MIC > 64 mg/L to fosfomycin, 8 isolates (1.8%) demonstrated MIC > 64 mg/L to berberine hydrochloride, and 271 isolates (60.1%) demonstrated MIC > 1 mg/L to doxycycline. Comparing all 540 tested isolates, a correlation of r = 0.50 (P < 0.001) between meropenem and ceftriaxone MIC was observed. In 24 ceftriaxone-decreased susceptibility isolates, all isolates showed an MIC ≤ 0.125 mg/L for meropenem, 1 isolate (4.2%) showed an MIC > 64 mg/L for fosfomycin, 1 isolate (4.2%) showed an MIC > 64 mg/L for berberine hydrochloride, and 13 isolates (54.2%) showed an MIC > 1 mg/L for doxycycline. In 87 azithromycin resistant isolates, all isolates showed an MIC ≤ 0.125 mg/L for meropenem, 2 isolates (2.3%) showed an MIC > 64 mg/L for fosfomycin, 4 isolates (4.6%) showed an MIC > 64 mg/L for berberine hydrochloride, and 64 isolates (73.6%) showed an MIC > 1 mg/L for doxycycline. CONCLUSION: The in vitro results suggest that meropenem might be a promising treatment option for resistant gonococcal infections, while the effects of fosfomycin and berberine hydrochloride should be further evaluated as potential therapeutic agents. The effectiveness of these drugs in animal experiments and clinical use may need further study. Dove 2020-12-15 /pmc/articles/PMC7751583/ /pubmed/33364794 http://dx.doi.org/10.2147/IDR.S278020 Text en © 2020 Zheng et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Zheng, Xiao-Li Xu, Wen-Qi Liu, Jing-Wei Zhu, Xiao-Yu Chen, Shao-Chun Han, Yan Dai, Xiu-Qin Goodman, Isabelle Griffin Budjan, Christoph Chen, Xiang-Sheng Yin, Yue-Ping Evaluation of Drugs with Therapeutic Potential for Susceptibility of Neisseria Gonorrhoeae Isolates from 8 Provinces in China from 2018 |
title | Evaluation of Drugs with Therapeutic Potential for Susceptibility of Neisseria Gonorrhoeae Isolates from 8 Provinces in China from 2018 |
title_full | Evaluation of Drugs with Therapeutic Potential for Susceptibility of Neisseria Gonorrhoeae Isolates from 8 Provinces in China from 2018 |
title_fullStr | Evaluation of Drugs with Therapeutic Potential for Susceptibility of Neisseria Gonorrhoeae Isolates from 8 Provinces in China from 2018 |
title_full_unstemmed | Evaluation of Drugs with Therapeutic Potential for Susceptibility of Neisseria Gonorrhoeae Isolates from 8 Provinces in China from 2018 |
title_short | Evaluation of Drugs with Therapeutic Potential for Susceptibility of Neisseria Gonorrhoeae Isolates from 8 Provinces in China from 2018 |
title_sort | evaluation of drugs with therapeutic potential for susceptibility of neisseria gonorrhoeae isolates from 8 provinces in china from 2018 |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7751583/ https://www.ncbi.nlm.nih.gov/pubmed/33364794 http://dx.doi.org/10.2147/IDR.S278020 |
work_keys_str_mv | AT zhengxiaoli evaluationofdrugswiththerapeuticpotentialforsusceptibilityofneisseriagonorrhoeaeisolatesfrom8provincesinchinafrom2018 AT xuwenqi evaluationofdrugswiththerapeuticpotentialforsusceptibilityofneisseriagonorrhoeaeisolatesfrom8provincesinchinafrom2018 AT liujingwei evaluationofdrugswiththerapeuticpotentialforsusceptibilityofneisseriagonorrhoeaeisolatesfrom8provincesinchinafrom2018 AT zhuxiaoyu evaluationofdrugswiththerapeuticpotentialforsusceptibilityofneisseriagonorrhoeaeisolatesfrom8provincesinchinafrom2018 AT chenshaochun evaluationofdrugswiththerapeuticpotentialforsusceptibilityofneisseriagonorrhoeaeisolatesfrom8provincesinchinafrom2018 AT hanyan evaluationofdrugswiththerapeuticpotentialforsusceptibilityofneisseriagonorrhoeaeisolatesfrom8provincesinchinafrom2018 AT daixiuqin evaluationofdrugswiththerapeuticpotentialforsusceptibilityofneisseriagonorrhoeaeisolatesfrom8provincesinchinafrom2018 AT goodmanisabellegriffin evaluationofdrugswiththerapeuticpotentialforsusceptibilityofneisseriagonorrhoeaeisolatesfrom8provincesinchinafrom2018 AT budjanchristoph evaluationofdrugswiththerapeuticpotentialforsusceptibilityofneisseriagonorrhoeaeisolatesfrom8provincesinchinafrom2018 AT chenxiangsheng evaluationofdrugswiththerapeuticpotentialforsusceptibilityofneisseriagonorrhoeaeisolatesfrom8provincesinchinafrom2018 AT yinyueping evaluationofdrugswiththerapeuticpotentialforsusceptibilityofneisseriagonorrhoeaeisolatesfrom8provincesinchinafrom2018 |